Edward E. Koval
Corporate Officer/Principal bei GERON CORPORATION
Profil
Edward E.
Koval is currently the Chief Business Officer & Executive Vice President at Geron Corp.
He previously worked as the Senior Vice President-Corporate Development at X-Chem, Inc. from 2013 to 2020 and as the Vice President-Business & Strategic Corporate Development at Veloxis Pharmaceuticals A from 2010 to 2012.
He also served as the Chief Business Officer at Zebiai Therapeutics, Inc. Mr. Koval received his undergraduate degree from New York University, his graduate degree from Rensselaer Polytechnic Institute, and his MBA from MIT Sloan School of Management.
Aktive Positionen von Edward E. Koval
| Unternehmen | Position | Beginn |
|---|---|---|
| GERON CORPORATION | Corporate Officer/Principal | 01.12.2021 |
Ehemalige bekannte Positionen von Edward E. Koval
| Unternehmen | Position | Ende |
|---|---|---|
X-Chem, Inc. (Massachusetts)
 X-Chem, Inc. (Massachusetts) Packaged SoftwareTechnology Services X-Chem, Inc. operates as a biotechnology company. Its uses its DEX DNA encoded libraries and platform to discover small molecule leads against high-value therapeutic targets. The company was founded by Richard W. Wagner, Brant C. Binder, Matthew A. Clark, and Gordon M. Binder in 2009 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01.01.2020 |
Zebiai Therapeutics, Inc.
 Zebiai Therapeutics, Inc. Packaged SoftwareTechnology Services Zebiai Therapeutics, Inc. develops artificial intelligence to predict and optimize novel small molecule modulators for challenging drug targets. The company was founded by Richard Wagner and is headquartered in Chestnut Hill, MA. | Corporate Officer/Principal | - |
| VELOXIS PHARMACEUTICALS A/S | Corporate Officer/Principal | - |
Ausbildung von Edward E. Koval
| New York University | Undergraduate Degree |
| Rensselaer Polytechnic Institute | Graduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GERON CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Zebiai Therapeutics, Inc.
Zebiai Therapeutics, Inc. Packaged SoftwareTechnology Services Zebiai Therapeutics, Inc. develops artificial intelligence to predict and optimize novel small molecule modulators for challenging drug targets. The company was founded by Richard Wagner and is headquartered in Chestnut Hill, MA. | Technology Services |
X-Chem, Inc. (Massachusetts)
X-Chem, Inc. (Massachusetts) Packaged SoftwareTechnology Services X-Chem, Inc. operates as a biotechnology company. Its uses its DEX DNA encoded libraries and platform to discover small molecule leads against high-value therapeutic targets. The company was founded by Richard W. Wagner, Brant C. Binder, Matthew A. Clark, and Gordon M. Binder in 2009 and is headquartered in Waltham, MA. | Technology Services |
